MIRA Pharmaceuticals, Inc. - Common Stock (NQ: MIRA )

1.900 -0.290 (-13.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MIRA Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
MIRA Pharmaceuticals stock rises as new preclinical data reveal its oral ketamine analog Ketamir-2 is 60% more effective than gabapentin in pain relief. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Via ACCESSWIRE
Peering Into Mira Pharmaceuticals's Recent Short Interest
Via Benzinga
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
Via ACCESSWIRE
(MIRA) - Analyzing Mira Pharmaceuticals's Short Interest
Via Benzinga
Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game
Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game 
Via News Direct
Topics Cannabis
Exposures Cannabis
Why Mira Shares Are Trading Higher Today
MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) shares are trading higher Friday following the announcement of promising new preclinical data for its lead development product, Ketamir-2. Here's what you need... 
Via Benzinga
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
Via ACCESSWIRE
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025 
Via News Direct
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
Via ACCESSWIRE
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action
Via ACCESSWIRE
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
Via ACCESSWIRE
The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End
The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End 
Via News Direct
MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies
MIRA Pharmaceuticals stock surges on promising preclinical results of oral ketamine analog, Ketamir-2, showing 100% pain threshold normalization in rats, positioning it as a potential breakthrough for... 
Via Benzinga
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Heico, PDD Holdings And 3 Stocks To Watch Heading Into Monday
Via Benzinga
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
Via ACCESSWIRE
MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024
MIRA stock results show that Mira Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
Via ACCESSWIRE
Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?
A look at the most-searched tickers on Benzinga Pro for the month of July shows some familiar names like Tesla, Nvidia and Apple. Here's a look at the others. 
Via Benzinga
MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year
MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year 
Via News Direct
Topics Cannabis
Exposures Cannabis
Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data
MIRA Pharmaceuticals stock surged on Thursday following new preclinical data on Ketamir-2, MIRA's novel oral ketamine analog, highlighting its unique selectivity and favorable safety profile for... 
Via Benzinga
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?
Mira Pharmaceuticals stock is falling on Tuesday but that's only after shares of MIRA underwent a massive rally on Monday. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning! 
Via InvestorPlace
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.